Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.
about
Blockade of endogenous B7-H1 suppresses antibacterial protection after primary Listeria monocytogenes infectionProgrammed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancerImmune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatmentNew targeted treatments for non-small-cell lung cancer - role of nivolumabCurrent status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyPD-1/PD-L1 blockade in cancer treatment: perspectives and issuesCTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their InhibitionHuman Cancer Immunotherapy with PD-1/PD-L1 BlockadeThe programmed death-1 immune-suppressive pathway: barrier to antitumor immunityOvercoming T cell exhaustion in infection and cancerLung cancer: a classic example of tumor escape and progression while providing opportunities for immunological interventionOptimal management of metastatic melanoma: current strategies and future directionsHarnessing immunosurveillance: current developments and future directions in cancer immunotherapyTumor infiltrating lymphocytes in ovarian cancerUpdate on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape.Combination Approaches with Immune-Checkpoint Blockade in Cancer TherapyCirculating and disseminated tumor cells: diagnostic tools and therapeutic targets in motionImmunoregulation in Fungal DiseasesImmune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacyAnti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potentialPD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cellsNivolumab in melanoma: latest evidence and clinical potentialPD-L1 regulates the development, maintenance, and function of induced regulatory T cellsB7-H1 expression in vestibular schwannomas.FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy.Targeting macrophage anti-tumor activity to suppress melanoma progression.B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells.Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burdenRational combinations of immunotherapeutics that target discrete pathways.Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.Prostate cancer and inflammation: the evidence.CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells.At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.Vaccines against human carcinomas: strategies to improve antitumor immune responses.The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment.Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype.Inhibitors of B7-CD28 costimulation in urologic malignancies.PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy.Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.
P2860
Q24652520-BDDCD06A-AF2F-4F98-8185-DB4130DB0561Q24685406-857FA285-5F8F-4833-AF41-38EAA67E81B7Q26738359-3F6E95DB-94EB-4AA8-A345-DEB9E81BE193Q26740988-56506AD0-64CD-4289-8C80-DE798D55C85BQ26745516-4EEB0D5D-5EA4-40ED-AF41-B4313D9AEE49Q26768641-37C3822D-735A-4311-9190-656914853D30Q26777563-D653776D-5123-4958-B6CD-8DA3E046E699Q26786108-42640024-6230-4EA4-894B-AF3AD5DE6C3BQ26829847-AE21B0F0-4A99-45D9-86E3-30C02B332E98Q26829885-C0A03071-7962-42FA-BBEE-3A6BA2D09CA8Q26850218-7F505572-CDE0-4FDA-B77D-1CE91E8111D8Q26997338-F1CF33EC-77E3-4E36-862C-49E166684817Q27021570-09959522-8E37-478E-AC9D-4C911D1E83B1Q27021878-A500B2BA-B239-4D49-B347-E76FAD453EB0Q27691824-D2C00A86-8DAA-42C3-B957-8F8091A22748Q28066199-3F3DE5D1-591B-4EA2-BE9D-711242041972Q28066285-BE43E7EB-562A-4E77-BFAE-7B98E9358592Q28074776-ECDCBC06-B57B-4CBC-83C4-F56C6A9BD02FQ28082914-9E94531D-BA23-4062-8E6A-CCB971AA8AD9Q28084942-54CA9E46-A8C3-4F42-A095-AB0811884149Q28242808-372E9415-6770-435A-A4D1-89800E0F40ADQ28258598-305E3CDB-D56A-47E4-83AB-595606BE164CQ30080038-0E7205F5-2BB7-4A29-ADC8-02B450407913Q30387475-28065F01-2A97-4F30-AA0E-2B32E32560EBQ33320890-9F800459-E028-450E-8C30-648282CEE502Q33566997-F15D7FBC-3B27-4AD1-8AC0-247DE769D577Q33574520-31BA99B7-6009-4F55-AF95-D541B711CEFDQ33576170-D813AC96-01B2-4518-8AAF-D522A7C330C6Q33606144-040B9511-DCE6-4425-950A-3BC4FD67FDB3Q33606150-971F8FFF-21F6-4160-99F0-9932A38B0F58Q33642321-1A300A3A-36E6-44D3-BFA9-D6100384636EQ33722711-BE4D67C6-C9BE-4787-9BC3-4FD330E9B054Q33732329-2D4E5D1F-E4D0-4B6C-B8DE-B5D18C9C800CQ33734281-CAA1627A-0E7D-44FF-A337-1E22E575A42DQ33736218-325C6652-8648-46CD-9FB3-E021D783B6E4Q33754618-47AD216E-6CB5-4A2C-A753-E0C22E4CE393Q33827752-719EAA7B-94E1-4929-88BB-41E0466CE261Q33839204-44AFA0DC-6273-42C4-BAA1-E344EC24A80FQ33887448-877198CF-E6BE-40E0-AF3B-C60CE803C723Q33889105-A1F7F3DA-997A-45C3-A339-A572DE2D782C
P2860
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Blockade of B7-H1 and PD-1 by ...... s cancer therapeutic immunity.
@ast
Blockade of B7-H1 and PD-1 by ...... s cancer therapeutic immunity.
@en
Blockade of B7-H1 and PD-1 by ...... s cancer therapeutic immunity.
@nl
type
label
Blockade of B7-H1 and PD-1 by ...... s cancer therapeutic immunity.
@ast
Blockade of B7-H1 and PD-1 by ...... s cancer therapeutic immunity.
@en
Blockade of B7-H1 and PD-1 by ...... s cancer therapeutic immunity.
@nl
prefLabel
Blockade of B7-H1 and PD-1 by ...... s cancer therapeutic immunity.
@ast
Blockade of B7-H1 and PD-1 by ...... s cancer therapeutic immunity.
@en
Blockade of B7-H1 and PD-1 by ...... s cancer therapeutic immunity.
@nl
P2093
P1433
P1476
Blockade of B7-H1 and PD-1 by ...... s cancer therapeutic immunity.
@en
P2093
Cecilia Rietz
Dallas B Flies
Fumiya Hirano
Gefeng Zhu
Haidong Dong
Hideto Tamura
Julie S Lau
Katsumi Kaneko
Koji Tamada
Lieping Chen
P304
P407
P577
2005-02-01T00:00:00Z